Core Viewpoint - Tiger Med's stock price has shown a decline of 4.42% year-to-date, with significant drops over various trading periods, indicating potential challenges in the market [1][2]. Financial Performance - For the period from January to September 2025, Tiger Med reported a revenue of 5.026 billion yuan, a year-on-year decrease of 0.82%, while the net profit attributable to shareholders increased by 25.45% to 1.020 billion yuan [2]. - Cumulative cash dividends since the A-share listing amount to 2.458 billion yuan, with 1.154 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 6.01% to 48,400, with an average of 0 shares per shareholder [2]. - The top circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 25.097 million shares, and other notable funds such as China Europe Medical Health Mixed A and Huabao CSI Medical ETF [3]. Market Activity - On November 26, Tiger Med's stock rose by 2.08% to 51.92 yuan per share, with a trading volume of 154 million yuan and a turnover rate of 0.53% [1]. - The stock has experienced a net inflow of 8.478 million yuan from major funds, with significant buying and selling activity noted [1]. Business Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, specializes in providing professional clinical research services for pharmaceutical and health-related products, covering phases I to IV of clinical trials [1]. - The company's revenue composition includes 52.60% from clinical trial-related services and 45.21% from clinical trial technical services [1]. Industry Classification - Tiger Med is classified under the pharmaceutical and biological sector, specifically in medical services and medical research outsourcing [2]. - The company is associated with various concept sectors, including mid-cap, margin financing, social security heavy positions, medical devices, and internet healthcare [2].

Core Viewpoint - Juyuan Yinhai's stock price has shown fluctuations with a recent increase of 2.10%, while the company has reported a year-to-date stock price increase of 11.31% and a significant rise in net profit for the first nine months of 2025 [1][2]. Financial Performance - For the period from January to September 2025, Juyuan Yinhai achieved a revenue of 687 million yuan, representing a year-on-year growth of 2.83%. The net profit attributable to shareholders was approximately 42.79 million yuan, marking a substantial increase of 127.43% [2]. - The company has distributed a total of 472 million yuan in dividends since its A-share listing, with 151 million yuan distributed over the past three years [3]. Stock Market Activity - As of November 24, Juyuan Yinhai's stock was trading at 19.00 yuan per share, with a market capitalization of 7.756 billion yuan. The stock has experienced a trading volume of 67.24 million yuan and a turnover rate of 0.88% [1]. - The company has seen a net inflow of main funds amounting to 541,200 yuan, with significant buying activity from large orders [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders for Juyuan Yinhai was 56,100, reflecting a decrease of 3.84% from the previous period. The average number of circulating shares per person increased by 3.99% to 7,212 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 3.0537 million shares, while new shareholder Jin Ying Technology Innovation Stock A holds 3 million shares [3].

资料显示，杭州泰格医药科技股份有限公司位于浙江省杭州市滨江区西兴街道聚工路19号盛大科技园A 座18层，成立日期2004年12月15日，上市日期2012年8月17日，公司主营业务涉及为国内外医药及健康 相关产品的研究开发提供专业临床研究服务,业务范围主要包括I至IV期临床试验技术服务、数据管理及 统计分析、注册申报、临床试验现场服务、SMO服务、医学检测服务、医学资料翻译、医学影像诊断 服务和培训服务。主营业务收入构成为：临床试验相关服务及实验室服务52.60%，临床试验技术服务 45.21%，其他(补充)2.19%。 泰格医药所属申万行业为：医药生物-医疗服务-医疗研发外包。所属概念板块包括：互联医疗、中盘、 融资融券、社保重仓、医疗器械等。 11月24日，泰格医药盘中上涨2.02%，截至10:24，报50.59元/股，成交1.69亿元，换手率0.59%，总市值 435.59亿元。 截至9月30日，泰格医药股东户数4.84万，较上期减少6.01%；人均流通股0股，较上期增加0.00%。2025 年1月-9月，泰格医药实现营业收入50.26亿元，同比减少0.82%；归母净利润10.20亿元，同比增长 25.4 ...

Core Viewpoint - The stock of Tongrentang has experienced fluctuations, with a recent decline of 2.04%, reflecting a mixed performance in the market and a decrease in main capital inflow [1] Financial Performance - For the period from January to September 2025, Tongrentang reported a revenue of 4.915 billion yuan, a year-on-year decrease of 14.27%, while the net profit attributable to shareholders increased by 4.45% to 907 million yuan [2] - Cumulative cash dividends since the A-share listing amount to 8.321 billion yuan, with 2.429 billion yuan distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders for Tongrentang is 71,100, a slight decrease of 0.14% from the previous period, with an average of 15,762 circulating shares per shareholder, down by 0.67% [2] - The second-largest circulating shareholder is E Fund's ChiNext ETF, holding 20.8508 million shares, a decrease of 3.7464 million shares from the previous period [3] Stock Market Activity - As of November 20, the stock price of Tongrentang is 12.46 yuan per share, with a total market capitalization of 21.078 billion yuan [1] - The stock has seen a year-to-date increase of 6.55%, but has declined by 4.52% over the last five trading days [1]

11月20日，泰格医药盘中下跌2.00%，截至10:53，报51.32元/股，成交2.64亿元，换手率0.90%，总市值 441.88亿元。 资金流向方面，主力资金净流出2263.55万元，特大单买入253.23万元，占比0.96%，卖出287.90万元， 占比1.09%；大单买入4660.36万元，占比17.64%，卖出6889.23万元，占比26.08%。 泰格医药今年以来股价跌5.53%，近5个交易日跌13.21%，近20日跌2.49%，近60日跌22.59%。 资料显示，杭州泰格医药科技股份有限公司位于浙江省杭州市滨江区西兴街道聚工路19号盛大科技园A 座18层，成立日期2004年12月15日，上市日期2012年8月17日，公司主营业务涉及为国内外医药及健康 相关产品的研究开发提供专业临床研究服务,业务范围主要包括I至IV期临床试验技术服务、数据管理及 统计分析、注册申报、临床试验现场服务、SMO服务、医学检测服务、医学资料翻译、医学影像诊断 服务和培训服务。主营业务收入构成为：临床试验相关服务及实验室服务52.60%，临床试验技术服务 45.21%，其他(补充)2.19%。 泰格医药所属申万行业为： ...

11月20日，东富龙盘中下跌2.01%，截至09:52，报16.55元/股，成交6441.71万元，换手率0.68%，总市 值126.74亿元。 分红方面，东富龙A股上市后累计派现17.82亿元。近三年，累计派现5.12亿元。 资金流向方面，主力资金净流出884.64万元，特大单买入0.00元，占比0.00%，卖出112.90万元，占比 1.75%；大单买入589.15万元，占比9.15%，卖出1360.89万元，占比21.13%。 东富龙今年以来股价涨25.62%，近5个交易日跌2.76%，近20日涨11.75%，近60日涨9.53%。 资料显示，东富龙科技集团股份有限公司位于上海市闵行区都会路1509号，成立日期1993年12月25日， 上市日期2011年2月1日，公司主营业务涉及医用冻干机及冻干系统的研发、设计、生产、销售和服务。 主营业务收入构成为：制剂事业部44.92%，生物工艺事业部29.83%，工程事业部9.19%，食品事业部 9.16%，售后服务与配件6.81%，其他(补充)0.09%。 东富龙所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：互联医疗、基因测序、生 物制造、合成 ...

Core Insights - Innovation Medical's stock price decreased by 2.03% on November 19, trading at 21.24 CNY per share with a total market capitalization of 9.373 billion CNY [1] - The company has seen a significant stock price increase of 166.83% year-to-date, but has experienced declines of 9.50% over the last five trading days, 9.69% over the last twenty days, and 14.49% over the last sixty days [1] - The company has been active in the stock market, appearing on the "Dragon and Tiger List" 19 times this year, with the most recent appearance on October 20, where it recorded a net buy of 242 million CNY [1] Financial Performance - For the period from January to September 2025, Innovation Medical reported a revenue of 597 million CNY, a year-on-year decrease of 2.11%, while the net profit attributable to shareholders was 4.7244 million CNY, reflecting a year-on-year increase of 116.97% [2] - The company has a primary business focus on medical services, which accounts for 99.73% of its revenue, with other income contributing only 0.27% [1] Shareholder Information - As of September 30, the number of shareholders for Innovation Medical reached 130,200, an increase of 58.75% from the previous period, while the average number of circulating shares per shareholder decreased by 37.01% to 3,196 shares [2] Dividend Information - Since its A-share listing, Innovation Medical has distributed a total of 55.8729 million CNY in dividends, with no dividends paid in the last three years [3]

Core Viewpoint - Tiger Med's stock price has experienced a decline of 3.17% year-to-date, with a significant drop of 21.49% over the past 60 days, indicating potential challenges in the market [1] Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1] - The main business segments include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, clinical trial site services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1] - The revenue composition is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1] Financial Performance - For the period from January to September 2025, Tiger Med reported a revenue of 5.026 billion yuan, a year-on-year decrease of 0.82%. However, the net profit attributable to the parent company was 1.020 billion yuan, reflecting a year-on-year increase of 25.45% [2] - The company has distributed a total of 2.458 billion yuan in dividends since its A-share listing, with 1.154 billion yuan distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders for Tiger Med was 48,400, a decrease of 6.01% from the previous period. The average circulating shares per person remained at 0 shares [2] - The top circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 25.097 million shares, and China Europe Medical Health Mixed A, which increased its holdings by 1.218 million shares [3]

Core Viewpoint - Zhongke Soft's stock price has experienced a decline of 1.45% year-to-date, with a recent drop of 2.01% on November 19, 2023, indicating potential challenges in market performance [1]. Financial Performance - For the period from January to September 2025, Zhongke Soft reported a revenue of 4.415 billion yuan, reflecting a year-on-year growth of 7.04%. However, the net profit attributable to shareholders decreased by 40.18% to 173 million yuan [2]. - Cumulatively, since its A-share listing, Zhongke Soft has distributed a total of 1.728 billion yuan in dividends, with 977 million yuan distributed over the past three years [3]. Shareholder and Market Activity - As of October 31, 2025, the number of shareholders for Zhongke Soft increased to 65,400, a rise of 0.47%. The average number of circulating shares per person decreased by 0.47% to 12,697 shares [2]. - The stock's trading activity on November 19 showed a net outflow of 11.36 million yuan in principal funds, with significant selling pressure from large orders [1]. Company Overview - Zhongke Soft, established on May 30, 1996, and listed on September 9, 2019, is based in Haidian District, Beijing. The company specializes in computer software development, with its main revenue sources being software development and services (71.83%) and system integration services (26.63%) [1]. - The company operates within the computer software development industry, specifically in vertical application software, and is associated with various concepts including MSCI China, margin financing, cloud computing, internet healthcare, and blockchain [1].

Core Viewpoint - Dian Diagnostics has shown a significant stock price increase of 48.75% year-to-date, despite a recent decline in revenue and net profit [1][2]. Group 1: Stock Performance - On November 18, Dian Diagnostics' stock rose by 2.23%, reaching 16.52 CNY per share, with a trading volume of 1.17 billion CNY and a turnover rate of 1.43%, resulting in a total market capitalization of 103.25 billion CNY [1]. - The stock has experienced a slight increase of 0.06% over the last five trading days, a 7.97% increase over the last 20 days, and a minor decline of 0.12% over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent occurrence on February 17 [1]. Group 2: Financial Performance - For the period from January to September 2025, Dian Diagnostics reported a revenue of 75.66 billion CNY, reflecting a year-on-year decrease of 18.28%, while the net profit attributable to shareholders was 56.70 million CNY, down 56.67% year-on-year [2]. - Since its A-share listing, the company has distributed a total of 10.99 billion CNY in dividends, with 7.12 billion CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Dian Diagnostics was 45,700, a decrease of 5.45% from the previous period, with an average of 10,974 shares held per shareholder, an increase of 5.76% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 10.56 million shares, a decrease of 4.23 million shares from the previous period [3].